ORIC - ORIC Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

81.31M

Cash

264.2M

Avg Qtr Burn

-19.11M

Short % of Float

18.42%

Insider Ownership

24.24%

Institutional Own.

75.39%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORIC-944 (PRC2 inhibitor) Details Prostate cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-533 (CD73 Inhibitor) Details Multiple myeloma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-114 (EGFR/HER2 Inhibitor) Details Solid tumor/s, Advanced malignancies	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 (Glucocorticoid Receptor Antagonist) + Xtandi (enzalutamide) Details Prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 (Glucocorticoid Receptor Antagonist) and nab-paclitaxel Details Solid tumor/s, Spasticity, Muscle control disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.